Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
← catalyst calendarNCT05303532 · readout in 134 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
214estimated
Sites
123
Countries
Argentina, Australia, Belgium +28
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-04-19 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-03-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cancer
Intervention
- Drug: Durvalumab
Primary outcome
what the primary-completion date above is the date OFNumber of participants with serious adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
measured From baseline up to follow up at 90 days after the last dose of study drug.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed